Unique ID issued by UMIN | UMIN000024211 |
---|---|
Receipt number | R000027868 |
Scientific Title | Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial |
Date of disclosure of the study information | 2016/09/29 |
Last modified on | 2016/09/28 20:08:47 |
Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial
Patient preference for monthly bisphosphonate versus weekly bisphosphonate
Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial
Patient preference for monthly bisphosphonate versus weekly bisphosphonate
Japan |
Patients with primary osteoporosis
Orthopedics |
Others
NO
To test the preference of Japanese patients with osteoporosis for monthly bisphosphonate and weekly bisphosphonate
Others
To test the convenience for monthly bisphosphonate and weekly bisphosphonate among Japanese patients with osteoporosis
Others
Others
Not applicable
Patient preference for either monthly bisphosphonate regimen or weekly bisphosphonate regimen among patients responding to the questionnaire after 6-month of treatment with monthly bisphosphonate (3-month) and weekly bisphosphonate (3-month)
Convenience of monthly bisphosphonate regimen compared tih weekly bisphosphonate regimen among patients responding to the questionnaire
Interventional
Parallel
Randomized
Cluster
Open -no one is blinded
Active
NO
NO
Institution is not considered as adjustment factor.
NO
Pseudo-randomization
2
Treatment
Medicine |
The clinics were randomized into two groups according to the dosing protocol, monthly bisphosphonate (3 months) followed by weekly bisphosphonate (3 months) or weekly bisphosphonate (3 months) followed by monthly bisphosphonate (3 months)
Monthly bisphosphonate: minodronate (50mg), weekly bisphosphonate: alendronate (35mg) or risedronate (17.5mg)
50 | years-old | < |
90 | years-old | > |
Male and Female
The inclusion criteria were age more than 50 years, a fully ambulatory status, a diagnosis of primary osteoporosis according to the Japanese diagnostic criteria and an osteoporosis treatment-naive status.
The exclusion criteria were a history of reflux esophagitis, gastric or duodenal ulcer, gastrectomy, renal failure, or bone diseases including cancer-induced bone loss, primary hyperparathyroidism, hyperthyroidism, Cushing syndrome, multiple myeloma, Paget's disease of the bone, rheumatoid arthritis, or osteogenesis imperfecta.
140
1st name | |
Middle name | |
Last name | Jun Iwamoto |
Keio University School of Medicine
Institute for Integrated Sports Medicine
35 Shinanomachi, Shinjuku-ku, Tokyo
03-3353-1211
jiwamotoexmed@gmail.com
1st name | |
Middle name | |
Last name | Jun Iwamoto |
Keio University School of Medicine
Institute for Integrated Sports Medicine
35 Shinanomchi, Shinjuku-ku, Tokyo
03-3353-1211
jiwamotoexmed@gmail.com
Clinical practice-based osteoporosis conference
The Waksman Foundation of Japan INC.
Non profit foundation
NO
東京都の病院およびクリニック
2016 | Year | 09 | Month | 29 | Day |
Published
Completed
2012 | Year | 09 | Month | 24 | Day |
2012 | Year | 09 | Month | 24 | Day |
2013 | Year | 04 | Month | 30 | Day |
2013 | Year | 06 | Month | 30 | Day |
2013 | Year | 06 | Month | 30 | Day |
2013 | Year | 07 | Month | 14 | Day |
2016 | Year | 09 | Month | 28 | Day |
2016 | Year | 09 | Month | 28 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027868